Carsten Denkert
Institute of Pathology
Charité Hospital
Campus Mitte
Schumannstr. 20/21
Germany
Name/email consistency: high
- Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Denkert, C., Kronenwett, R., Schlake, W., Bohmann, K., Penzel, R., Weber, K.E., Höfler, H., Lehmann, U., Schirmacher, P., Specht, K., Rudas, M., Kreipe, H.H., Schraml, P., Schlake, G., Bago-Horvath, Z., Tiecke, F., Varga, Z., Moch, H., Schmidt, M., Prinzler, J., Kerjaschki, D., Sinn, B.V., Müller, B.M., Filipits, M., Petry, C., Dietel, M. Virchows Arch. (2012)
- Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B.M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., von Törne, C., Weichert, W., Engels, K., Solbach, C., Schrader, I., Dietel, M., von Minckwitz, G. J. Clin. Oncol. (2010)
- A prognostic gene expression index in ovarian cancer - validation across different independent data sets. Denkert, C., Budczies, J., Darb-Esfahani, S., Györffy, B., Sehouli, J., Könsgen, D., Zeillinger, R., Weichert, W., Noske, A., Buckendahl, A.C., Müller, B.M., Dietel, M., Lage, H. J. Pathol. (2009)
- Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Denkert, C., Budczies, J., Weichert, W., Wohlgemuth, G., Scholz, M., Kind, T., Niesporek, S., Noske, A., Buckendahl, A., Dietel, M., Fiehn, O. Mol. Cancer (2008)
- Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1. Denkert, C., Thoma, A., Niesporek, S., Weichert, W., Koch, I., Noske, A., Schicktanz, H., Burkhardt, M., Jung, K., Dietel, M., Kristiansen, G. Prostate (2007)
- Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Denkert, C., Koch, I., von Keyserlingk, N., Noske, A., Niesporek, S., Dietel, M., Weichert, W. Mod. Pathol. (2006)
- Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Denkert, C., Budczies, J., Kind, T., Weichert, W., Tablack, P., Sehouli, J., Niesporek, S., Könsgen, D., Dietel, M., Fiehn, O. Cancer Res. (2006)
- Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Denkert, C., Weichert, W., Pest, S., Koch, I., Licht, D., Köbel, M., Reles, A., Sehouli, J., Dietel, M., Hauptmann, S. Cancer Res. (2004)
- Prognostic impact of cyclooxygenase-2 in breast cancer. Denkert, C., Winzer, K.J., Hauptmann, S. Clin. Breast Cancer (2004)
- Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Denkert, C., Weichert, W., Winzer, K.J., Müller, B.M., Noske, A., Niesporek, S., Kristiansen, G., Guski, H., Dietel, M., Hauptmann, S. Clin. Cancer Res. (2004)
- Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Denkert, C., Winzer, K.J., Müller, B.M., Weichert, W., Pest, S., Köbel, M., Kristiansen, G., Reles, A., Siegert, A., Guski, H., Hauptmann, S. Cancer (2003)
- Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Denkert, C., Fürstenberg, A., Daniel, P.T., Koch, I., Köbel, M., Weichert, W., Siegert, A., Hauptmann, S. Oncogene (2003)
